499 related articles for article (PubMed ID: 25490234)
1. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
2. EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics.
Hu Y
Curr Top Med Chem; 2017; 17(20):2233-2234. PubMed ID: 28799501
[No Abstract] [Full Text] [Related]
3. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
4. The design, annotation, and application of a kinase-targeted library.
Xi H; Lunney EA
Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
[TBL] [Abstract][Full Text] [Related]
5. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
6. Rational design of inhibitors that bind to inactive kinase conformations.
Liu Y; Gray NS
Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PARP modulators--current status and future therapeutic potential.
Penning TD
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
[TBL] [Abstract][Full Text] [Related]
8. SAR156497, an exquisitely selective inhibitor of aurora kinases.
Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
[TBL] [Abstract][Full Text] [Related]
9. Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Bikker JA; Brooijmans N; Wissner A; Mansour TS
J Med Chem; 2009 Mar; 52(6):1493-509. PubMed ID: 19239229
[No Abstract] [Full Text] [Related]
10. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Combs AP
J Med Chem; 2010 Mar; 53(6):2333-44. PubMed ID: 20000419
[No Abstract] [Full Text] [Related]
11. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
Verma SK; Knight SD
Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
[TBL] [Abstract][Full Text] [Related]
13. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
[TBL] [Abstract][Full Text] [Related]
14. Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.
Angiolini M
Future Med Chem; 2011 Mar; 3(3):309-37. PubMed ID: 21446845
[TBL] [Abstract][Full Text] [Related]
15. Exploring the scaffold universe of kinase inhibitors.
Hu Y; Bajorath J
J Med Chem; 2015 Jan; 58(1):315-32. PubMed ID: 25192260
[TBL] [Abstract][Full Text] [Related]
16. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
17. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
18. Design of targeted libraries against the human Chk1 kinase using PGVL Hub.
Peng Z; Hu Q
Methods Mol Biol; 2011; 685():321-36. PubMed ID: 20981531
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
20. When will small molecule lactate dehydrogenase inhibitors realize their potential in the cancer clinic?
Rani R; Kumar V
Future Med Chem; 2017 Jul; 9(11):1113-1115. PubMed ID: 28722474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
